KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Change in Accured Expenses data on record, last reported at $26.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 11.98% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $77.1 million, down 10.52%, while the annual FY2025 figure was $77.1 million, 10.52% down from the prior year.
  • Change in Accured Expenses reached $26.2 million in Q4 2025 per JAZZ's latest filing, down from $126.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $181.0 million in Q1 2025 and bottomed at -$256.4 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $22.4 million, with a median of $32.2 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 722.22% in 2021, then crashed 775.85% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $48.8 million in 2021, then surged by 203.41% to $148.1 million in 2022, then crashed by 64.21% to $53.0 million in 2023, then crashed by 43.92% to $29.7 million in 2024, then dropped by 11.98% to $26.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $26.2 million in Q4 2025, $126.3 million in Q3 2025, and -$256.4 million in Q2 2025.